News

Teclistamab induces deep responses in high-risk smouldering multiple myeloma in phase II trial

16 Nov 2026
Teclistamab induces deep responses in high-risk smouldering multiple myeloma in phase II trial

by ecancer reporter Nathan Jere

Fixed-duration teclistamab produced complete responses in about three-quarters of patients with high-risk smouldering multiple myeloma (HR-SMM), versus none given lenalidomide–dexamethasone (Rd), according to the randomised phase II ImmunoPRISM trial published in Nature Medicine.

The results suggest early BCMA-directed T-cell redirection can clear disease deeply, but follow-up is too short to show whether it prevents myeloma or improves survival.

Among randomised, treated patients, 29 of 39 (74%) receiving teclistamab achieved a complete response or better, the primary endpoint, versus none of 14 receiving Rd. Including six safety run-in patients, the rate was 77.8%, and 82.2% were negative for minimal residual disease (MRD) at 10⁻⁵.

HR-SMM is an asymptomatic plasma-cell disorder with a high risk of progression to myeloma. Daratumumab became the first approved treatment in 2025, based on the AQUILA trial (Dimopoulos et al., New England Journal of Medicine, 2025).

In the open-label trial, 60 patients were randomised 2:1 to teclistamab or Rd. A protocol amendment cut teclistamab to a maximum of 12 cycles (15 months); Rd was given for two years.

At a median follow-up of 24.5 months, two-year progression-free survival was 92% with teclistamab and 49% with Rd (HR, 0.15; 95% CI, 0.04–0.59). Progression included biochemical events; only five patients developed a myeloma-defining event, two with teclistamab and three with Rd.

"So we're expecting to see that these people that go into these deep remissions likely will not develop progression for a long, long time," Dr Omar Nadeem of Dana-Farber Cancer Institute, joint first author, told ecancer.

He added: "That is to be determined, but the possibility is there that some of this could potentially be a one-and-done curative type therapy for these patients."

Cytokine release syndrome occurred in 71.1% of teclistamab-treated patients, all grade 1–2, with no ICANS. Grade 3 infections occurred in 20% and 21% of the teclistamab and Rd arms, and grade 3–4 neutropenia in 36% and 29%. All teclistamab-treated patients received intravenous immunoglobulin. No deaths occurred.

Writing in a commentary in Nature Reviews Clinical Oncology, Professor María-Victoria Mateos of the University of Salamanca called the outcomes encouraging, but said "the small control group and limited number of events warrant caution".

She noted only 64% of patients met 20/2/20 high-risk criteria, daratumumab should now be the comparator in phase III trials, and the optimal treatment duration is unknown. MRD as a surrogate endpoint also needs validation in smouldering disease.

Other caveats include six of 20 Rd patients withdrawing before treatment and three teclistamab non-responders.

Dr Nadeem stressed that teclistamab is not approved for HR-SMM: "Right now, this is not something outside of this clinical trial that we can just use for these patients with high risk smouldering myeloma."

Phase III bispecific trials are recruiting, he said; one compares linvoseltamab with daratumumab (NCT07393282).

"Carefully designed randomized phase III trials will be needed to determine whether deep and durable responses translate into prolonged disease-free survival or, ultimately, cure, with an acceptable benefit–risk profile," she concluded.

 

Video: Watch an interview With Dr Omar Nadeem on the ImmunoPRISM trial here.

Article Reference: Nadeem, O., Cordas dos Santos, D.M., Magidson, S. et al. Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. Nat Med 32, 3812–3822 (2026). https://doi.org/10.1038/s41591-026-04642-w

Commentary Reference: Mateos, M.-V. T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma? Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01230-2

Nature Reviews commentary author Dr María-Victoria Mateos has received honoraria from lectures and advisory board involvement for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Kite, Oncopeptides, Pfizer, Regeneron, Sanofi and Stemline Menarini. The trial itself was supported by Johnson & Johnson.